Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Submit a Manuscript

Thank you for your interest in submitting a manuscript to the Journal of Invasive Cardiology. All submissions are processed through Editorial Manager. If this is your first time submitting, we ask that you create an account with Editorial Manager.

Click here to access Editorial Manager and set up your account: https://www.editorialmanager.com/jic

If you have previously submitted a manuscript to the JIC, you do not need to create a new account with Editorial Manager. You can simply use the log-in information from your prior submission.

Please read through the instructions for authors page before preparing your submission. 

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

News

Transcatheter Heart Valves
LANDMARK Trial: Meril Announces Successful Primary Outcomes of Next-Gen Myval THV Series in Major RCT
05/17/2024

Meril Life Sciences News

Meril Life Sciences News
Professor Serruys, Chairman & study director of the LANDMARK trial, said, "Myval THV series are novel next-gen THV devices; non-inferior to the Sapien and Evolut THV series. Myval THV series have a unique size matrix incorporating...
Professor Serruys, Chairman & study director of the LANDMARK trial, said, "Myval THV series are novel next-gen THV devices; non-inferior to the Sapien and Evolut THV series. Myval THV series have a unique size matrix incorporating...
Professor Serruys, Chairman &...
05/17/2024
Cath Lab Digest
Heart Failure
Implicity Earns FDA Clearance for New Heart Failure Prediction Algorithm
05/17/2024

Implicity News

Implicity News
SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of CIEDs, including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices...
SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of CIEDs, including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices...
SignalHF is unique in that the...
05/17/2024
Cath Lab Digest
Coronary Implants
DESyne BDS Plus RCT: Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES
05/16/2024

Elixir Medical News

Elixir Medical News
DESyne BDS Plus has a bioresorbable coating containing three drugs: two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor (sirolimus) designed for delivery of site-specific antithrombotic therapeutic.
DESyne BDS Plus has a bioresorbable coating containing three drugs: two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor (sirolimus) designed for delivery of site-specific antithrombotic therapeutic.
DESyne BDS Plus has a...
05/16/2024
Cath Lab Digest
Intravascular Lithotripsy
Primary Outcomes From PINNACLE I Clinical Trial Establish Safety and Effectiveness of Elixir Medical’s Hertz Contact IVL in Moderate to Severe Calcified Coronary Artery Lesions
05/16/2024

Elixir Medical News

Elixir Medical News
The novel LithiX Hertz Contact Intravascular Lithotripsy (IVL) system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal...
The novel LithiX Hertz Contact Intravascular Lithotripsy (IVL) system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal...
The novel LithiX Hertz Contact...
05/16/2024
Cath Lab Digest
Bioadaptors
BIOADAPTOR RCT Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years
05/16/2024

Elixir Medical News

Elixir Medical News
Elixir Medical announced two-year results from the BIOADAPTOR randomized controlled (1:1) trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent from 34 centers in Japan, Europe, and New...
Elixir Medical announced two-year results from the BIOADAPTOR randomized controlled (1:1) trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent from 34 centers in Japan, Europe, and New...
Elixir Medical announced...
05/16/2024
Cath Lab Digest
Intravascular Lithotripsy
FastWave Medical Granted Fifth Utility Patent Reflecting Continuous Expansion of IVL IP Portfolio
05/16/2024

FastWave Medical News

FastWave Medical News
The newly granted patent bolsters the innovative design of FastWave's next-generation IVL platform, aimed at overcoming challenges associated with treating calcified arteries in patients with occlusive vascular disease.
The newly granted patent bolsters the innovative design of FastWave's next-generation IVL platform, aimed at overcoming challenges associated with treating calcified arteries in patients with occlusive vascular disease.
The newly granted patent...
05/16/2024
Cath Lab Digest
IMAGING
One in Three People Die Due to Atherosclerosis: A New Initiative, REACT, Aims to Find New Ways to Prevent It
05/16/2024

Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) News

Centro Nacional de Investigaciones Ca...
“REACT will develop – at scale - methods to directly visualize the disease (atherosclerosis),” says Dr. Borja Ibáñez, Scientific Director of CNIC, cardiologist at Fundación Jiménez Díaz hospital, and leader of the Spanish part of the study.
“REACT will develop – at scale - methods to directly visualize the disease (atherosclerosis),” says Dr. Borja Ibáñez, Scientific Director of CNIC, cardiologist at Fundación Jiménez Díaz hospital, and leader of the Spanish part of the study.
“REACT will develop – at scale -...
05/16/2024
Cath Lab Digest
hypertension
Patient “Chronotype” Could Impact Best Time to Take Blood Pressure Medication
05/16/2024

University of Dundee News

University of Dundee News
Scientists observed that so-called “morning larks” (earlier chronotypes) who took their prescribed blood pressure medication in the morning were less likely to experience a heart attack than those who were “misaligned” and took it in the...
Scientists observed that so-called “morning larks” (earlier chronotypes) who took their prescribed blood pressure medication in the morning were less likely to experience a heart attack than those who were “misaligned” and took it in the...
Scientists observed that...
05/16/2024
Cath Lab Digest
Extreme exercise
JAMA: Exercise Does Not Accelerate Artery Plaque Buildup More Often Seen in Fitness Enthusiasts
05/16/2024

UT Southwestern Medical Center News

UT Southwestern Medical Center News ...
The study, which analyzed more than 8,700 participants from 1998-2019, provides important insight on whether people whose heart scans detect higher calcium should modify their exercise regimen to slow the plaque buildup in arteries.
The study, which analyzed more than 8,700 participants from 1998-2019, provides important insight on whether people whose heart scans detect higher calcium should modify their exercise regimen to slow the plaque buildup in arteries.
The study, which analyzed more...
05/16/2024
Cath Lab Digest
Pregnancy
Infertility Treatment Doubles Risk of Postpartum Heart Disease
05/15/2024

Rutgers University News

Rutgers University News
“We have been involved in a series of studies over the past few years that have found serious risks of heart disease and stroke to various high-risk patient populations within those initial 30 days after delivery – risks that could be...
“We have been involved in a series of studies over the past few years that have found serious risks of heart disease and stroke to various high-risk patient populations within those initial 30 days after delivery – risks that could be...
“We have been involved in a...
05/15/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

Transcatheter Heart Valves
LANDMARK Trial: Meril Announces Successful Primary Outcomes of Next-Gen Myval THV Series in Major RCT
05/17/2024

Meril Life Sciences News

Meril Life Sciences News
Professor Serruys, Chairman & study director of the LANDMARK trial, said, "Myval THV series are novel next-gen THV devices; non-inferior to the Sapien and Evolut THV series. Myval THV series have a unique size matrix incorporating...
Professor Serruys, Chairman & study director of the LANDMARK trial, said, "Myval THV series are novel next-gen THV devices; non-inferior to the Sapien and Evolut THV series. Myval THV series have a unique size matrix incorporating...
Professor Serruys, Chairman &...
05/17/2024
Cath Lab Digest
Heart Failure
Implicity Earns FDA Clearance for New Heart Failure Prediction Algorithm
05/17/2024

Implicity News

Implicity News
SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of CIEDs, including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices...
SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of CIEDs, including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices...
SignalHF is unique in that the...
05/17/2024
Cath Lab Digest
Coronary Implants
DESyne BDS Plus RCT: Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES
05/16/2024

Elixir Medical News

Elixir Medical News
DESyne BDS Plus has a bioresorbable coating containing three drugs: two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor (sirolimus) designed for delivery of site-specific antithrombotic therapeutic.
DESyne BDS Plus has a bioresorbable coating containing three drugs: two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor (sirolimus) designed for delivery of site-specific antithrombotic therapeutic.
DESyne BDS Plus has a...
05/16/2024
Cath Lab Digest
Intravascular Lithotripsy
Primary Outcomes From PINNACLE I Clinical Trial Establish Safety and Effectiveness of Elixir Medical’s Hertz Contact IVL in Moderate to Severe Calcified Coronary Artery Lesions
05/16/2024

Elixir Medical News

Elixir Medical News
The novel LithiX Hertz Contact Intravascular Lithotripsy (IVL) system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal...
The novel LithiX Hertz Contact Intravascular Lithotripsy (IVL) system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal...
The novel LithiX Hertz Contact...
05/16/2024
Cath Lab Digest
Bioadaptors
BIOADAPTOR RCT Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years
05/16/2024

Elixir Medical News

Elixir Medical News
Elixir Medical announced two-year results from the BIOADAPTOR randomized controlled (1:1) trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent from 34 centers in Japan, Europe, and New...
Elixir Medical announced two-year results from the BIOADAPTOR randomized controlled (1:1) trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent from 34 centers in Japan, Europe, and New...
Elixir Medical announced...
05/16/2024
Cath Lab Digest
Intravascular Lithotripsy
FastWave Medical Granted Fifth Utility Patent Reflecting Continuous Expansion of IVL IP Portfolio
05/16/2024

FastWave Medical News

FastWave Medical News
The newly granted patent bolsters the innovative design of FastWave's next-generation IVL platform, aimed at overcoming challenges associated with treating calcified arteries in patients with occlusive vascular disease.
The newly granted patent bolsters the innovative design of FastWave's next-generation IVL platform, aimed at overcoming challenges associated with treating calcified arteries in patients with occlusive vascular disease.
The newly granted patent...
05/16/2024
Cath Lab Digest
IMAGING
One in Three People Die Due to Atherosclerosis: A New Initiative, REACT, Aims to Find New Ways to Prevent It
05/16/2024

Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) News

Centro Nacional de Investigaciones Ca...
“REACT will develop – at scale - methods to directly visualize the disease (atherosclerosis),” says Dr. Borja Ibáñez, Scientific Director of CNIC, cardiologist at Fundación Jiménez Díaz hospital, and leader of the Spanish part of the study.
“REACT will develop – at scale - methods to directly visualize the disease (atherosclerosis),” says Dr. Borja Ibáñez, Scientific Director of CNIC, cardiologist at Fundación Jiménez Díaz hospital, and leader of the Spanish part of the study.
“REACT will develop – at scale -...
05/16/2024
Cath Lab Digest
hypertension
Patient “Chronotype” Could Impact Best Time to Take Blood Pressure Medication
05/16/2024

University of Dundee News

University of Dundee News
Scientists observed that so-called “morning larks” (earlier chronotypes) who took their prescribed blood pressure medication in the morning were less likely to experience a heart attack than those who were “misaligned” and took it in the...
Scientists observed that so-called “morning larks” (earlier chronotypes) who took their prescribed blood pressure medication in the morning were less likely to experience a heart attack than those who were “misaligned” and took it in the...
Scientists observed that...
05/16/2024
Cath Lab Digest
Extreme exercise
JAMA: Exercise Does Not Accelerate Artery Plaque Buildup More Often Seen in Fitness Enthusiasts
05/16/2024

UT Southwestern Medical Center News

UT Southwestern Medical Center News ...
The study, which analyzed more than 8,700 participants from 1998-2019, provides important insight on whether people whose heart scans detect higher calcium should modify their exercise regimen to slow the plaque buildup in arteries.
The study, which analyzed more than 8,700 participants from 1998-2019, provides important insight on whether people whose heart scans detect higher calcium should modify their exercise regimen to slow the plaque buildup in arteries.
The study, which analyzed more...
05/16/2024
Cath Lab Digest
Pregnancy
Infertility Treatment Doubles Risk of Postpartum Heart Disease
05/15/2024

Rutgers University News

Rutgers University News
“We have been involved in a series of studies over the past few years that have found serious risks of heart disease and stroke to various high-risk patient populations within those initial 30 days after delivery – risks that could be...
“We have been involved in a series of studies over the past few years that have found serious risks of heart disease and stroke to various high-risk patient populations within those initial 30 days after delivery – risks that could be...
“We have been involved in a...
05/15/2024
Cath Lab Digest

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement